Liu Jun-Guo, Wu Jing, Wang Jun, Shu Gui-Ming, Wang Yi-Jun, Lou Cheng, Zhang Jinjuan, Du Zhi
1 Department of Surgery, Third Central Hospital of Tianjin, Third Central Clinical College of Tianjin Medical University , Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin, China .
2 Department of Ultrasonography, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin Medical University , Tianjin, China .
J Laparoendosc Adv Surg Tech A. 2018 Sep;28(9):1053-1060. doi: 10.1089/lap.2017.0744. Epub 2018 Mar 12.
Hilar cholangiocarcinoma (HCCA) is a rare tumor, usually associated with obstructive jaundice and unfavorable prognosis. Obstructive jaundice can affect the liver, kidney, heart, and the immune system of the patients. Currently, controversy exists in whether preoperative biliary drainage (PBD) is of any benefit to the patients, and the best way for PBD in patients with resectable HCCA of malignant biliary obstruction remains to be determined.
To compare the clinical outcomes and effectiveness of endoscopic biliary drainage (EBD) treatment with those of percutaneous transhepatic biliary drainage (PTBD) treatment in patients with malignant biliary obstruction caused by resectable HCCA.
The databases including MEDLINE, EMBASE, PubMed, CBM (China Biological Medicine Database), and CNKI were employed to identify the clinic trials on EBD versus PTBD for malignant biliary obstruction associated with resectable HCCA from January 2008 to October 2017. A systematic review and meta-analysis were carried out.
Six trials were identified and included in this study. Overall, the differences in technical success rate, R0 resection, incidence of total complication after resection, postoperative hospitalization time, resection time, and recurrence were not statistically significant between the EBD group and PTBD group (all P > .05). However, the incidence of total complications after EBD treatment is higher than that after PTBD treatment (P < .05).
For patients with obstructive jaundice associated with HCCA, current evidence indicate no superiority of PTBD over EBD regarding clinical feasibility and success rate, but data suggest a better clinical safety of PTBD compared with EBD in short-term postoperation. In long-term evaluation, the differences in clinical outcomes are not statistically significant between PTBD and EBD.
肝门部胆管癌(HCCA)是一种罕见肿瘤,通常伴有梗阻性黄疸且预后不良。梗阻性黄疸可影响患者的肝脏、肾脏、心脏及免疫系统。目前,术前胆道引流(PBD)对患者是否有益存在争议,对于可切除的HCCA合并恶性胆道梗阻患者,PBD的最佳方式仍有待确定。
比较内镜下胆道引流(EBD)治疗与经皮经肝胆道引流(PTBD)治疗可切除HCCA所致恶性胆道梗阻患者的临床结局及有效性。
利用包括MEDLINE、EMBASE、PubMed、CBM(中国生物医学数据库)和CNKI在内的数据库,检索2008年1月至2017年10月关于EBD与PTBD治疗可切除HCCA相关恶性胆道梗阻的临床试验。进行系统评价和荟萃分析。
本研究共纳入6项试验。总体而言,EBD组与PTBD组在技术成功率、R0切除率、切除术后总并发症发生率、术后住院时间、切除时间及复发率方面差异均无统计学意义(均P>0.05)。然而,EBD治疗后总并发症发生率高于PTBD治疗后(P<0.05)。
对于HCCA合并梗阻性黄疸患者,现有证据表明在临床可行性和成功率方面PTBD并不优于EBD,但数据显示PTBD在术后短期内的临床安全性优于EBD。在长期评估中,PTBD与EBD在临床结局方面差异无统计学意义。